Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?

• Recent studies have indicated that the risk of thromboembolic disease (VTE) in users of combined oral contraceptive pills (COCs) varies not only with estrogen dose, but also with the progestogen in pills with the same estrogen dose. The aim of this article is to discuss sex hormone binding globulin (SHBG) as a marker of estrogenicity and as a surrogate indicator for the potential risk of VTE in users of COC.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)

Nyckelord

Biological Markers

blood

Contraceptives

Oral

Combined

adverse effects

Cyproterone Acetate

Desogestrel

Female

Humans

Levonorgestrel

Norgestrel

analogs & derivatives

Norpregnenes

Predictive Value of Tests

Risk Factors

Sex Hormone-Binding Globulin

metabolism

Venous Thrombosis

chemically induced

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)